Articles

UC Davis and NeuroPointDX to launch biomarker panel

New test will target autism diagnosis for children as young as 18 months
Written byLori Lesko
| 3 min read

SACRAMENTO, Calif.—With an aim of launching a new biomarker test panel that could offer the first objective test leading to the earliest diagnosis of autism spectrum disorder (ASD) thus far, investigators at the MIND Institute at the University of California, Davis (UC Davis) and NeuroPointDX have identified a group of blood metabolites that could help detect some children with ASD as young as 18 months old.

The research was published Sept. 6 in the journal Biological Psychiatry, as part of the 1,100 subject Children’s Autism Metabolome Project (CAMP), reportedly the largest ASD metabolism study ever attempted. The article reports on how investigators at the UC Davis MIND Institute and NeuroPointDX, a division of Stemina Biomarker Discovery, have identified specific alterations in metabolic profiles that can detect sizable subsets of individuals with autism.

In this latest study, the research team compared blood metabolites—specifically, amino acids—in 516 children with ASD and 164 children showing typical development.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.